Department of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, 210008, China; Department of Pathology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210000, China.
Department of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, 210008, China.
Hum Pathol. 2021 Sep;115:37-46. doi: 10.1016/j.humpath.2021.02.003. Epub 2021 Feb 23.
In addition to hepatoid adenocarcinoma (HAC), gastric adenocarcinoma with enteroblastic differentiation (GAED) and common adenocarcinoma (COM) could also show hepatoid differentiation, which presents a poor prognosis. To elucidate the histogenesis and development of gastric cancer with hepatoid differentiation, we identified 55 cases by histological morphology and a panel of markers, including α-fetoprotein (AFP), Glypican 3 (GPC3) and SALL4, then clinicopathological parameters, pathomorphological characteristics, mucin phenotypes, molecular features, Immunoscore and survival analysis were assessed. A mixture of three types (COM + GAED + HAC) was most commonly observed in the same case, and typical transitions between each histological subtype were frequently seen. Hyaline globule and pink amorphous substance were often present. HER2 was amplified in 21.8% of cases. All the tumors showed intestinal phenotype (69.1%) and mixed gastric/intestinal phenotype (30.9%) and were all defined to chromosomal instable (CIN)/genomically stable (GS) group. Considering that 83.6% cases presented TP53 gene mutation phenotype and 61.8% cases showed ≥10% aberrant E-cadherin expression, the precise molecule classification is ambiguous. Survival analysis showed that patients with high SALL4 expression, high preoperative serum AFP level, or low Immunoscore had a significantly poor overall survival (OS). Moreover, SALL4, HER2, and Immunoscore had an independent influence on OS. In conclusion, we suggest that the development of gastric adenocarcinoma with hepatoid differentiation might a continuously progressive profile: from intestinal-type COM adenocarcinoma to GAED and then HAC. CIN/GS subtypes might be where they belonged. SALL4, HER2, and Immunoscore may be potential therapeutic targets.
除了肝样腺癌(HAC)外,具有肠上皮分化的胃腺癌(GAED)和普通腺癌(COM)也可能表现出肝样分化,这预示着预后不良。为了阐明具有肝样分化的胃癌的组织发生和发展,我们通过组织形态学和一系列标志物(包括甲胎蛋白(AFP)、Glypican 3(GPC3)和 SALL4)鉴定了 55 例病例,然后评估了临床病理参数、病理形态特征、黏蛋白表型、分子特征、免疫评分和生存分析。同一病例中最常见的是三种类型(COM+GAED+HAC)的混合,并且每种组织学亚型之间经常出现典型的过渡。透明小体和粉红色无定形物质经常存在。HER2 在 21.8%的病例中扩增。所有肿瘤均表现为肠型(69.1%)和混合胃/肠型(30.9%),均被定义为染色体不稳定(CIN)/基因组稳定(GS)组。考虑到 83.6%的病例表现出 TP53 基因突变表型,61.8%的病例表现出≥10%异常的 E-钙黏蛋白表达,因此精确的分子分类不明确。生存分析表明,高 SALL4 表达、高术前血清 AFP 水平或低免疫评分的患者总生存期(OS)显著较差。此外,SALL4、HER2 和免疫评分对 OS 有独立影响。总之,我们建议胃腺癌伴肝样分化的发展可能是一个连续进展的过程:从肠型 COM 腺癌到 GAED 再到 HAC。CIN/GS 亚型可能是它们所属的类型。SALL4、HER2 和免疫评分可能是潜在的治疗靶点。